A conceptual framework for rational target selection and combinatorial design is provided for rational target selection and combinatorial design of next-generation CAR T-cell therapies with improved precision and durability against solid tumors.
Recent advances, persistent challenges, and emerging strategies for CAR-T cell therapy in pediatric solid tumors are summarized and rational combination strategies involving CAR-T cell therapy with chemotherapy, radiotherapy, and immune checkpoint inhibitors aimed at improving therapeutic efficacy and safety are discus...
Yu-Miao Mai, Zi-Wen Wang, Juan Wang et al.· Experimental Hematology & On...· 0 citations
It is proposed that integrating principles from developmental biology, tumor evolution, and immuno-engineering will be essential to unlocking the therapeutic potential of oncofetal antigen-directed CAR-T therapies in solid tumors.
Sam Sebastian Smith, A. Klampatsa· Frontiers in Cell and Develo...· 0 citations
This review comprehensively examines the current landscape of CAR-T cell therapy for colon cancer, focusing on its underlying mechanisms, recent clinical advances, major challenges, and future perspectives.
Arifa Raza, M. Raza, Junaid Khan et al.· Pathology, Research and Prac...· 0 citations
It is indicated that no single engineering strategy is sufficient to overcome the interconnected barriers of GBM, and future progress in GBM CAR therapy will therefore depend on combining complementary solutions rather than improving only one CAR feature.
Aleksandra Królikowska, Katarzyna Białkowska· International Immunopharmaco...· 0 citations
The biological mechanisms underlying resistance to CAR-T therapy in solid tumors are examined and emerging combination strategies designed to enhance tumor recognition, trafficking, persistence, and antitumor activity are critically evaluated.
Wei Cheng, Mei-Lan Liu, Yu-Hua Diao et al.· Cancer Biome and Targeted Th...· 0 citations
Recent advances in CAR-T cell engineering are summarized, the major target antigens investigated to date are discussed, a comprehensive overview of the available clinical evidence, and the key biological and clinical challenges that must be addressed are examined to improve future therapeutic outcomes.
Ahmad Farajzadeh, Mahmoud Mahmoudi, Soroush Yazdani et al.· International Immunopharmaco...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
